findmyKOL
Clinical trialNCT04555811CompletedPhase 1Interventional

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

SponsorMasonic Cancer Center, University of MinnesotaEnrollment7Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaNHLNon Hodgkin Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Minnesota

    Minneapolis, Minnesota, United States

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Sept 2020
Primary completion
8 Feb 2023
Completion
30 Nov 2023
Last update posted
9 Jul 2024
Registered enrollment
7
Registry id
NCT04555811
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.